This three-part agenda — legislation, executive action, and tariffs — will reduce the living standards and raise costs for ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...